The U.S. Food and Drug Administration (FDA) approved a supplemental application for Xeljanz XR (tofacitinib) on February 21, 2025. This approval, identified as NDA 208246 S-25, specifically pertains to the efficacy of the drug.
Background
Tofacitinib, marketed as Xeljanz and Xeljanz XR, is a drug developed by Pfizer. Supplemental applications for existing approved drugs typically address new information related to the drug's profile, such as new indications, dosing regimens, or updates to its efficacy or safety based on new clinical or post-market data. This particular approval focuses on the efficacy aspect of the drug.
What this means
This supplemental approval for Xeljanz XR (tofacitinib) indicates that the FDA has reviewed and acknowledged new data supporting the drug's effectiveness. While the specific details of the efficacy update are not provided in the summary, such regulatory actions are significant as they often lead to updates in the drug's official prescribing information. This could potentially expand its approved uses, clarify its effectiveness in existing indications, or refine patient populations for which it is deemed effective. Clinicians and patients can anticipate updated labeling to reflect this regulatory decision.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for NDA 208246 S-25, concerning Xeljanz XR (tofacitinib), was recorded on 2025-02-21 on accessdata.fda.gov.